



SmithKline Beecham
Clinical Laboratories

November 23, 1990

A. Bert Davis, Regional Administrator
U.S. Nuclear Regulatory Commission, Region III
799 Roosevelt Road
Glen Ellyn, IL 60137

RE: DOCKET NO. 03017925
LICENSE NO. 22-20069-01

Dear Mr. Davis:

In response to your letter, dated November 2, 1990, I would like to note that we use by-product materials with quantities on hand not exceeding the amounts indicated in the right hand column, as listed in the table below:

Isotope -----	Amount -----
I-125	4 mCi
Cs-137	0.2 uCi
I-129	1.0 uCi

Please note that the latter two isotopes are in the form of sealed sources, and that the first is received as part of prepackaged diagnostic reagent kits, is in the form of 125-I-T4, 125-I-T3, 125-I-Folate and 125-I-Protein (TSH and Prolactin) and is used for radioimmunoassay testing.

Discussions with several members of your staff lead me to conclude that the quantities of isotope that we use are sufficiently small that we do not have to file either a decommissioning funding plan or a certificate that financial assurance of decommissioning has been provided.

If this is not correct, please advise as soon as possible so that we may provide the necessary documentation on a timely basis.

Thank you,

Peter B. Mockridge, Ph.D.

PBM:pms

RECEIVED
NOV 26 1990
REGION III

9102140083 910207
REG3 LIC30
22-20069-01 PDR